Clinical trials: Hepatitis C Virus (HCV)
HIV, Hepatitis C
Effects of Motivational Interviewing on Risky Injecting Practices Among Injecting Drug Users (IDUs)
The purpose of this study is to evaluate the effects of a brief motivational intervention in reducing risky injection practices among injecting drug users (IDUs).
- Trial name
- NCT00794391
- Testing
- Motivational interviewing, Educational intervention
- Where
- Canada
- Volunteers
- 219 people
- Sponsor
- Université de Sherbrooke
Hepatitis C
Timing and Duration of Acute Hepatitis C Treatment
Spontaneous resolution of acute hepatitis C infection cannot be predicted and the majority of cases persist and become chronic. This randomized trial assesses the efficacy and safety of peginterferon alfa-2b.
- Trial name
- NCT00241618
- Testing
- Pegylated interferon alpha 2, Ribavirin
- Where
- 3 sites in Egypt
- Volunteers
- 180 people
- Sponsor
- Ain Shams University
Hepatitis C Virus Infection
Study to Investigate Pharmacokinetics, Safety and Efficacy of Sofosbuvir/Velpatasvir/Voxilaprevir (SOF/VEL/VOX) Fixed Dose Combination (FDC) in Adolescents and Children With Chronic Hepatitis C Virus (HCV) Infection
The primary objective of this study is to evaluate the steady-state pharmacokinetics (PK) and confirm the age-appropriate dose of sofosbuvir/velpatasvir/voxilaprevir (SOF/VEL/VOX) fixed-dose combination (FDC) in pediatric…
- Trial name
- NCT03820258
- Testing
- SOF/VEL/VOX
- Where
- 10 sites in Italy, Poland and 1 more
- Volunteers
- 21 people
- Sponsor
- Gilead Sciences
Hepatitis C
Daclatasvir, Asunaprevir Plus Ribavirin for HCV Genotype 1b Without NS5A RAV
A single-arm, multi-center study of HCV-1b patients without baseline non-structure protein (NS5A) resistance-associated variants.
- Trial name
- NCT03004625
- Testing
- daclatasvir, asunaprevir, Ribavirin
- Where
- Taiwan
- Volunteers
- 70 people
- Sponsor
- Kaohsiung Medical University Chung-Ho Memorial Hospital
Hepatitis C
A Study Evaluating GS-9620 in Treatment Naive Subjects With Chronic Hepatitis C
Dose cohorts may be dosed with one of up to 4 possible total weekly doses (0.3 mg, 1 mg, 2 mg, 4 mg). Dose escalation or repetition will be governed by pre-specified safety and activity rules.
- Trial name
- NCT01591668
- Testing
- Single Ascending Dose Cohorts GS-9620, Multiple Ascending Dose Cohorts GS-9620
- Where
- 11 sites in United States, Puerto Rico
- Volunteers
- 51 people
- Sponsor
- Gilead Sciences
Beta-Thalassemia, Hepatitis C
Hyalornic Acid Level in β-Thalassemic Children Treated for Hepatitis C Virus
Patients with transfusion dependent Beta Thalassemia suffer from a high incidence of Hepatitis C infection especially in developed countries as Egypt.
- Trial name
- NCT03961828
- Testing
- Ledipasvir 90 MG / Sofosbuvir 400 MG [Harvoni]
- Where
- Egypt
- Volunteers
- 50 people
- Sponsor
- Tanta University
Substance Use, HIV Infections
Kentucky Communities and Researchers Engaging to Halt the Opioid Epidemic (CARE2HOPE)
This study will test the effects of an intervention to reduce substance use and related harms among people leaving rural jails or otherwise involved in the criminal justice system.
- Conditions
- Substance Use, HIV Infections, HCV Infection, Sexually Transmitted Infections (Not HIV or Hepatitis)
- Trial name
- NCT04134767
- Testing
- Health Linkage, Overdose Education
- Where
- United States
- Volunteers
- 234 people, healthy volunteers welcome
- Sponsor
- April M Young
Hepatitis C Virus
TMC435-TiDP16-C125 - Study in Healthy Volunteers to Evaluate the Potential of TMC435 to Increase the Sensitivity of the Skin Towards Exposure to Sun Light
The purpose of the study is to evaluate the potential effect of TMC435 on the sensitivity of the skin towards exposure to sunlight.
- Trial name
- NCT01124799
- Testing
- TMC435, Ciprofloxacin
- Volunteers
- 49 people, healthy volunteers welcome
- Sponsor
- Tibotec Pharmaceuticals, Ireland
Hepatitis C, HIV Coinfection
Supporting Treatment Outcomes Among PWID
The goal of this study is to improve HCV care continuum outcomes for people who inject drugs (PWID), reduce potential onward transmission to others and improve HIV outcomes among those who are HIV/HCV coinfected.
- Trial name
- STOP-C (NCT04652804)
- Testing
- Low intensity HCV treatment adherence support, Medium intensity HCV treatment adherence support, High intensity HCV treatment adherence support
- Where
- India
- Volunteers
- 3,000 people
- Sponsor
- Johns Hopkins University
HCV Infection ( Genotype 4) in CKD Patients
Treatment of CKD Patients With HCV
The goal of this clinical trial is to evaluate the optimal drug therapy of HCV in CKD Patients different stages with or without compensated cirrhosis.
- Trial name
- HCV/CKD (NCT07770984)
- Testing
- SOF+DCV, OBV/PTV/r) ± ribavirin (RBV)
- Where
- Egypt
- Volunteers
- 50 people
- Sponsor
- Tanta University
Chronic Hepatitis C
Multiple Dose Study In Treatment Naive Subjects Infected With Hepatitis C Virus
The purpose of this study is to determine the antiviral effect following three days of dosing with BMS-824393 in chronically genotype subtype 1a and 1b Hepatitis C virus (HCV) infected subjects.
- Trial name
- NCT00971308
- Testing
- BMS-824393
- Where
- 6 sites in United States
- Volunteers
- 37 people
- Sponsor
- Bristol-Myers Squibb
Hepatitis C, PrEP
HepC Micro-elimination on MSM and TGW Population.
This is an observational study, in which a single visit will be carried out, which includes a questionnaire on sexual habits and in which the possibility of carrying out a screening for Hepatitis C will be offered.
- Conditions
- Hepatitis C, PrEP, Drugs of Abuse
- Trial name
- NCT06847958
- Where
- Spain
- Volunteers
- 13,161 people, healthy volunteers welcome
- Sponsor
- Projecte dels NOMS Hispanosida
Hepatitis C
Dose Escalation Study of Interleukin-7 (IL-7) and Bitherapy in HCV Genotype 1 or 4 Patients Resistant to Bitherapy Alone
This study is designed to evaluate the safety of biological active dose of a new experimental drug, IL-7, in combination with standard bi-therapy in patients with Hepatitis C chronic infection identified as non responders to the…
- Trial name
- Eclipse 2 (NCT01025297)
- Testing
- Interleukin-7
- Where
- 8 sites in France, Italy and 1 more
- Volunteers
- 18 people
- Sponsor
- Cytheris SA
Hepatitis C
Quantification of Side Effects During Hepatitis C Therapy
This study aims to assess the frequency and severity of adverse events during Hepatitis C therapy with or without first generation protease inhibitors.
- Trial name
- NCT02545400
- Where
- Austria
- Volunteers
- 108 people
- Sponsor
- Medical University of Graz
Hepatitis C
SHO-SAIKO-TO for Patients With Chronic Hepatitis C: A Phase II Study
Researchers want to see whether Sho-saiko-to (SST) can help in patients with chronic hepatitis C. Chronic hepatitis C may cause swelling within the liver and this can lead to scar tissue.
- Trial name
- NCT00590564
- Testing
- Sho-saiko-to
- Where
- United States
- Volunteers
- 42 people
- Sponsor
- Memorial Sloan Kettering Cancer Center
Acute Hepatitis C
HepNet Acute HCV IV - LDV/SOF FDC in Acute Genotype 1 Hepatitis C Virus Infection
This is an open-label, single arm, multicenter, pilot-study to compare the efficacy and safety of LDV/SOF fixed dose combination (FDC) in subjects with acute genotype 1 HCV infection.
- Trial name
- NCT02309918
- Testing
- LDV/SOF FDC
- Where
- 20 sites in Germany
- Volunteers
- 20 people
- Sponsor
- HepNet Study House, German Liverfoundation
Hepatitis C, Chronic
Efficacy and Safety of 24 vs 48 Weeks of Pegetron® (Peginterferon Alfa-2b + Ribavirin) in Naïve Genotype 1 Hepatitis C (Study P05016)(TERMINATED)
This is a Phase IIIB randomized, controlled, multi-centre, open-label study of 24 versus 48 weeks therapy with Pegetron® (peginterferon alfa-2b + ribavirin) at standard doses in naïve Hepatitis C Virus (HCV) genotype 1 high viral…
- Trial name
- NCT00423800
- Testing
- Combination of pegylated interferon alfa-2b (PEG) and ribavirin (RBV)
- Volunteers
- 56 people
- Sponsor
- Merck Sharp & Dohme LLC
Chronic Hepatitis C
Study to Determine the Safety and Effectiveness of Antiviral Combination Therapy to Treat Hepatitis C Virus (HCV) in Patients Who Have Previously Not Received the Standard of Care
The purpose of the study is to determine whether therapy with the combination of PSI-7977 and daclatasvir (BMS-790052) with or without ribavirin is effective in treating hepatitis C virus (HCV) infection when given for 12 or 24…
- Trial name
- NCT01359644
- Testing
- PSI-7977, Daclatasvir, Ribavirin
- Where
- 18 sites in United States, Puerto Rico
- Volunteers
- 350 people
- Sponsor
- Bristol-Myers Squibb
Hepatitis C Virus
Safety and Efficacy of Sofosbuvir-based Regimens in Clinical Practice for the Treatment of Chronic Hepatitis C Virus Infection in India
This study will evaluate the safety and efficacy of sofosbuvir (SOF)-based regimens administered as per the approved prescribing information in adults with chronic hepatitis C virus (HCV) infection treated in routine clinical…
- Trial name
- NCT02592057
- Testing
- SOF
- Where
- 26 sites in India
- Volunteers
- 532 people
- Sponsor
- Gilead Sciences
Hepatocellular Carcinoma
The Assesment of MMP-1 Genotypes Polymorphism as a Risk Factor for HCC in Chronic HCV Patients With LC
Egypt is an endemic area of HCV.Cirrhosis and HCC are the most serious complications of chronic HCV infection.Some studies noted that the risk of HCC increased 17-fold among HCV-infected patients compared with anti-HCV negative…
- Trial name
- NCT03722628
- Testing
- MMP1 genotypes polymorphism
- Volunteers
- 200 people, healthy volunteers welcome
- Sponsor
- Assiut University
The first 1,020 results can be paged through. Add a filter or change the sort order to reach the rest.